Ciclosporin A and Acute Myocardial Infarction
Recruitment status was Active, not recruiting
Beyond its immunosuppressive properties, ciclosporine A (CsA) can also inhibit the opening of a mitochondrial mega-channel called the permeability transition pore (mPTP). Opening of the mPTP plays a key role in cardiomyocyte death during reperfusion following a prolonged ischemic insult. Ciclosporin A has been shown to reduce infarct size when administered at reperfusion in experimental models. The objective of the present study is to determine whether administration of CsA at reperfusion in patients with ongoing acute myocardial infarction treated by coronary angioplasty might reduce infarct size.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Protection by Ciclosporine A During Reperfused Acute Myocardial Infarction.|
- Infarct size evaluated primarily by the area under the curve of CK and troponin I release over the first 72 hours of reperfusion.
- Myocardial contractile reserve assessed by dobutamine echocardiography at day 5.
- No reflow evaluated by MRI at day 5
- Recovery of myocardial contraction assessed by echocardiography and MRI at month 3
|Study Start Date:||September 2004|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00403728
|Lyon, France, 69677|
|Principal Investigator:||Michel Ovize, MD||Hospices Civils de Lyon|